Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
April 24, 2006
- Industry Calls For Exemption from Supply of Original Drugs in Full Range of Strengths
April 24, 2006
- Seretide Lowers Mortality of COPD: GSK
April 17, 2006
- R&D NEWS IN BRIEF
April 17, 2006
- Pharmacists Want More Info. on Changes in Packaging, Formulation
April 17, 2006
- Sankyo Daiichi Aims for \100 Bil. Sales in CHC Business with Acquisition of Zepharma
April 17, 2006
- Boehringer Ingelheim to Remain Independent: Dr Banchi
April 17, 2006
- Major Drug Firms Offer Better Child-Rearing Leave than Law Requires
April 17, 2006
- Mochida Aims for Sales of \79 Bil. in New 3-Year Plan
April 17, 2006
- Nihon Medi-Physics Expands Consultation Services Regarding PET-CT
April 17, 2006
- Kissei Licenses Novel Diabetes Treatment to GSK
April 17, 2006
- Daiichi to Market Intrathecal Gagalon with Synchromed Infusion System
April 17, 2006
- Astellas Acquires Worldwide Rights to Amevive
April 17, 2006
- MEDICAL DEVICE NEWS IN BRIEF
April 17, 2006
- Kirin, Intercell to Develop Antibodies to Treat Pneumonia
April 17, 2006
- JMA's Relationship with LDP Needs Mending: Dr Karasawa
April 17, 2006
- Mr Iwasaki to Improve Labor-Management Relations via Dialogue: Pfizer Japan
April 17, 2006
- SEMINAR
April 17, 2006
- Kowa, Nikken's Integration Plan Accredited
April 17, 2006
- Sawai Expands Business with Wholesalers, Dispensing Pharmacies
April 17, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…